Carelon (formerly AIM) · Hereditary Cancer Panel · US health-plan appeal rights

Hereditary Cancer Panel denied for failing step therapy by Carelon (formerly AIM)?

Q: How long do I have to appeal a Carelon (formerly AIM) Hereditary Cancer Panel denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-25

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Carelon (formerly AIM) typically requires

NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.

Source policy: Carelon Medical Benefits Management — Genetic Testing UM

What works in the appeal

GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.

The Carelon (formerly AIM) angle on Hereditary Cancer Panel

## Why Carelon Denied Your Hereditary Cancer Panel Under Step Therapy

Carelon (formerly AIM Specialty Health) applies a step-therapy-style sequencing requirement to genetic testing: the insurer may require that single-gene or limited-panel tests be performed before approving a comprehensive multi-gene hereditary cancer panel. This approach is based on a tiered-testing model that is increasingly at odds with current professional guidelines, which in many clinical scenarios support upfront multi-gene panel testing rather than sequential single-gene testing.

## Why This Denial Is Appealable

Step-therapy (or "sequence of testing") requirements for genetic panels are clinically contested. Professional guideline bodies have moved toward recommending broader upfront panel testing for many hereditary cancer indications because: sequential single-gene testing is slower and more expensive in aggregate; it delays risk-reduction decision-making; and multi-gene panels detect pathogenic variants in genes that would never be reached via sequential testing. Your prescriber can document why skipping the sequential step is clinically appropriate for your specific situation, which is the standard step-therapy exception basis under virtually all health plan policies.

## Federal Appeal Framework

Internal Appeal: ACA and ERISA §503 provide the right to a full-and-fair internal appeal. File within the deadline on your denial letter. Many states also have specific step-therapy exception laws that may apply.
External Review: Under ACA §2719, after a final internal denial, you are entitled to independent external review by an accredited IRO, generally within four months of the final internal denial. Expedited review is available for urgent oncologic situations.
State Step-Therapy Protections: Many states have enacted step-therapy exception laws requiring insurers to grant exceptions within specified timeframes when clinical criteria are met. Check whether your state law applies to your plan type.

## Concrete Appeal Steps and Timeline

1. Identify the required prior step — determine exactly what prior test Carelon requires before the multi-gene panel is covered. 2. Have your prescriber document the clinical rationale for bypassing sequential testing, citing applicable professional guidelines. 3. File internal appeal with step-therapy exception documentation. 4. Invoke state step-therapy exception law if applicable to your plan type. 5. File external review if internal appeal is denied.

## Documentation to Gather

Prescriber letter documenting why the step-therapy sequence is clinically inappropriate for your specific indication and why multi-gene upfront testing is supported by current guidelines
Current applicable guideline from the relevant professional organization (such as NCCN) supporting upfront multi-gene panel testing for the specific indication — obtain directly from that organization
Clinical records documenting personal history, family history, and any prior single-gene test results
If prior sequential tests were performed: those results and an explanation of why they were insufficient
Any documentation of clinical urgency requiring faster results than sequential testing would allow

## Criteria-Mapping Structure

For each step-therapy exception criterion in Carelon's policy, document the chart fact:

| Exception Criterion | Your Supporting Evidence | |---|---| | Required prior step is clinically contraindicated or inappropriate | Prescriber letter with clinical rationale; guideline support for upfront panel | | Required prior step was already tried (if applicable) | Prior test reports with dates and results | | Delay from sequential testing poses clinical risk | Prescriber documentation of urgency; planned surgical or treatment decision timeline | | Guideline supports bypassing step | Current guideline language from applicable professional organization |

Step-therapy exception requests for hereditary cancer panels are among the stronger appeal categories when backed by current professional guidelines, because many guidelines have explicitly endorsed upfront panel testing over the sequential approach that Carelon's policy requires.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other insurers on Hereditary Cancer Panel

Other denial reasons for Carelon (formerly AIM) Hereditary Cancer Panel

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.